The CARES Approach: Improving Glycemic, Cardiovascular and Renal Outcomes
Exit Survey
Questions marked with a
*
are required
20%
Meta-analyses for the SGLT2 inhibitor trials EMPA-REG, CANVAS, and DECLARE-TIMI demonstrated which of the following?
Reduced hazard ratios for the progression of chronic kidney disease with SGLT2 inhibitors vs placebo
Reduced hazard ratios for the development of bone fractures with SGLT2 inhibitors vs placebo
Increased hazard ratios for MACE with SGLT2 inhibitors vs placebo
Increased hazard ratios for heart failure hospitalizations with SGLT2 inhibitors vs placebo
Next
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
Loading...